Illumina, Inc. $ILMN Shares Acquired by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd significantly increased its stake in Illumina, Inc. by 664.5%, now owning 3,058 shares worth $243,000, as reported in its latest SEC filing.
• Illumina's stock has seen mixed ratings from analysts, with six firms labeling it as a Buy and two as a Sell, resulting in a consensus rating of "Hold".
• Illumina reported earnings of $1.19 per share for the last quarter, exceeding estimates, but experienced a 4.8% decline in revenue compared to the previous year.

Bayforest Capital Ltd grew its stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 664.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,058 shares of the life sciences company's stock after acquiring an additional 2,658 shares during the quarter. Bayforest Capital Ltd's holdings in Illumina were worth $243,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of ILMN. Rise Advisors LLC increased its stake in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after acquiring an additional 224 shares during the last quarter. Rakuten Securities Inc. increased its stake in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after acquiring an additional 270 shares during the last quarter. Center for Financial Planning Inc. acquired a new stake in shares of Illumina in the 1st quarter worth $33,000. Fourth Dimension Wealth LLC acquired a new stake in shares of Illumina in the 4th quarter worth $40,000. Finally, PFS Partners LLC increased its stake in shares of Illumina by 400.0% in the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company's stock worth $40,000 after acquiring an additional 400 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ILMN has been the subject of a number of recent analyst reports. Piper Sandler cut their price objective on Illumina from $190.00 to $185.00 and set an "overweight" rating for the company in a research report on Thursday, May 15th. Royal Bank Of Canada set a $124.00 price objective on Illumina in a research report on Tuesday, September 2nd. Citigroup downgraded Illumina from a "hold" rating to a "strong sell" rating and cut their price objective for the stock from $85.00 to $80.00 in a research report on Wednesday, July 9th. Stephens set a $110.00 price objective on Illumina and gave the stock an "overweight" rating in a research report on Monday, August 4th. Finally, Evercore ISI raised their price objective on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Six equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $123.06.

Illumina Stock Performance

NASDAQ ILMN opened at $99.31 on Friday. The company has a market cap of $15.26 billion, a P/E ratio of 12.57, a P/E/G ratio of 2.15 and a beta of 1.43. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. The stock has a 50-day moving average of $99.56 and a two-hundred day moving average of $88.57. Illumina, Inc. has a 1-year low of $68.70 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.17. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%.Illumina's revenue was down 4.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.36 EPS. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.